18F-FDG PET during stereotactic body radiotherapy for stage i lung tumours cannot predict outcome: A pilot study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 6, 2011, Pages 1059-1063

  Wiegman, Erwin M ^a   Pruim, Jan ^a   Ubbels, Jan F ^a   Groen, Harry J M ^a   Langendijk, Johannes A ^a   Widder, Joachim ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

FDG PET; Lung tumours; Response monitoring; SBRT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EARLY CANCER; FEMALE; HUMAN; INOPERABLE CANCER; LUNG CANCER; MALE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; CANCER STAGING; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RADIOSURGERY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOSURGERY; TREATMENT OUTCOME;

EID: 79954571101     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1706-8     Document Type: Article

References (19)

1. MS Reif MA Socinski MP Rivera 2000 Evidence-based medicine in the treatment of non-small-cell lung cancer Clin Chest Med 21 1 107 120 10763093 10.1016/S0272-5231(05)70011-3 1:STN:280:DC%2BD3c3is1ejsQ%3D%3D ix (Pubitemid 30183776)
2. FJ Lagerwaard S Senan JP van Meerbeeck WJ Graveland Rotterdam Oncological Thoracic Study Group 2002 Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer? Radiother Oncol 63 2 151 157 12063004 10.1016/S0167-8140(02)00009-9 (Pubitemid 34628403)
3. A Chi Z Liao NP Nguyen J Xu B Stea R Komaki 2010 Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications Radiother Oncol 94 1 1 11 20074823 10.1016/j.radonc.2009.12.008
4. T Ishimori T Saga Y Nagata Y Nakamoto T Higashi M Mamede, et al. 2004 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy Ann Nucl Med 18 8 669 674 15682847 10.1007/BF02985960 (Pubitemid 40215915)
5. DJ Hoopes M Tann JW Fletcher JA Forquer PF Lin SS Lo, et al. 2007 FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer Lung Cancer 56 2 229 234 17353064 10.1016/j.lungcan.2006.12.009 (Pubitemid 46590486)
6. MA Henderson DJ Hoopes JW Fletcher PF Lin M Tann CT Yiannoutsos, et al. 2010 A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy Int J Radiat Oncol Biol Phys 76 3 789 795 19473777 10.1016/j.ijrobp.2009.02.051
7. R Boellaard WJ Oyen CJ Hoekstra OS Hoekstra EP Visser AT Willemsen, et al. 2008 The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials Eur J Nucl Med Mol Imaging 35 12 2320 2333 18704407 10.1007/s00259-008-0874-2
8. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 13 1773 1782 10673991 10.1016/S0959-8049(99)00229-4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D (Pubitemid 29512308)
9. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
10. CW Hurkmans JP Cuijpers FJ Lagerwaard J Widder UA van der Heide D Schuring, et al. 2009 Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study Radiat Oncol 4 1 19138400 10.1186/1748-717X-4-1
11. http://clinicaltrials.gov/ct2/show/NCT00840749
12. Y Sugawara DK Braun PV Kison JE Russo KR Zasadny RL Wahl 1998 Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results Eur J Nucl Med 25 9 1238 1243 9724371 10.1007/s002590050290 1:STN:280:DyaK1czptFOisA%3D%3D (Pubitemid 28446048)
13. R Kubota S Yamada K Kubota K Ishiwata N Tamahashi T Ido 1992 Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography J Nucl Med 33 11 1972 1980 1432158 1:CAS:528:DyaK3sXns1aktw%3D%3D
14. A van Baardwijk G Bosmans A Dekker M van Kroonenburgh L Boersma S Wanders, et al. 2007 Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients Radiother Oncol 82 2 145 152 17258339 10.1016/j.radonc.2007.01.007
15. H Hautzel HW Müller-Gärtner 1997 Early changes in fluorine-18-FDG uptake during radiotherapy J Nucl Med 38 9 1384 1386 9293793 1:STN:280:DyaK2svjvVSiug%3D%3D (Pubitemid 27386195)
16. M Murayama N Harada T Kakiuchi D Fukumoto A Kamijo AT Kawaguchi, et al. 2009 Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice J Nucl Med 50 2 290 295 19164228 10.2967/jnumed.108.057091
17. N Gupta H Gill G Graeber H Bishop J Hurst T Stephens 1998 Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions Chest 114 4 1105 1111 9792584 10.1378/chest.114.4.1105 1:STN:280:DyaK1M%2FgslSksg%3D%3D (Pubitemid 28495909)
18. K Suga Y Kawakami A Hiyama K Sugi K Okabe T Matsumoto, et al. 2009 Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions Ann Nucl Med 23 5 427 435 19437097 10.1007/s12149-009-0260-6
19. S Sanz-Viedma DA Torigian M Parsons S Basu A Alavi 2009 Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging Rev Esp Med Nucl 28 3 159 166 19558958 10.1016/S0212-6982(09)71360-6 1:STN:280:DC%2BD1MvkvFalsw%3D%3D